The first patients in a 600-patient Phase II study have been enrolled. The study will investigate the effects of Lu AA34893 on the depressive episodes in bipolar disorder and its potential to prevent occurrence of mania. Lu AA34893 was selected as a development candidate based on its convincing effect in preclinical animal models suggesting a potential to improve the treatment of mood disorder.
Anders Gersel Pedersen, senior vice president, head of development at Lundbeck, said: “This study marks the first entry into bipolar disorder for Lundbeck and if successful, Lu AA34893 will provide a completely new approach to treat the needs of patients with bipolar disorder.”